Kronos Bio (KRON) News Today $0.89 +0.01 (+1.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.88 -0.01 (-1.19%) As of 06/13/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRON Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Insider Selling: Kronos Bio, Inc. (NASDAQ:KRON) CEO Sells 24,838 Shares of StockJune 7, 2025 | insidertrades.comKronos Bio, Inc. (NASDAQ:KRON) CEO Deborah Knobelman Sells 24,838 SharesKronos Bio, Inc. (NASDAQ:KRON - Get Free Report) CEO Deborah Knobelman sold 24,838 shares of the business's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $0.87, for a total value of $21,609.06. Following the sale, the chief executive officer now directly owns 139,422 shares in the company, valued at $121,297.14. This trade represents a 15.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.June 6, 2025 | marketbeat.comKronos Bio sends Cambridge lab space back to marketJune 5, 2025 | bizjournals.comKronos Bio Terminates Cambridge Lease AgreementJune 5, 2025 | tipranks.comOrca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial OfficerJune 4, 2025 | finance.yahoo.comKRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRONMay 4, 2025 | businesswire.comConcentra To Acquire Kronos BioMay 3, 2025 | nasdaq.comKronos Bio (KRON) Projected to Announce Quarterly Earnings on ThursdayKronos Bio (NASDAQ:KRON) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-kronos-bio-inc-stock/)May 3, 2025 | marketbeat.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRONMay 1, 2025 | prnewswire.comKronos Bio Agrees to Be Acquired by Concentra BiosciencesMay 1, 2025 | marketwatch.comShareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public ShareholdersMay 1, 2025 | businesswire.comKRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to ShareholdersMay 1, 2025 | businesswire.comKronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value RightMay 1, 2025 | finance.yahoo.comKronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value RightMay 1, 2025 | globenewswire.comKronos Bio, Inc. (NASDAQ:KRON) Sees Significant Decrease in Short InterestKronos Bio, Inc. (NASDAQ:KRON - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 611,600 shares, a drop of 18.2% from the March 15th total of 748,000 shares. Based on an average trading volume of 188,000 shares, the short-interest ratio is currently 3.3 days. Approximately 1.6% of the shares of the stock are sold short.April 22, 2025 | marketbeat.comShort Interest in Kronos Bio, Inc. (NASDAQ:KRON) Drops By 13.4%Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 748,000 shares, a drop of 13.4% from the February 28th total of 863,500 shares. Based on an average daily volume of 231,500 shares, the days-to-cover ratio is currently 3.2 days. Approximately 1.9% of the shares of the company are sold short.April 4, 2025 | marketbeat.comKronos Bio Reports 2024 Financial ResultsMarch 27, 2025 | tipranks.comKronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023)March 20, 2025 | finance.yahoo.comKronos Bio reports Q4 EPS (43c) vs. (43c ) last yearMarch 19, 2025 | markets.businessinsider.comKronos Bio (NASDAQ:KRON) Issues Earnings ResultsKronos Bio (NASDAQ:KRON - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13). Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%.March 19, 2025 | marketbeat.comKronos Bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 18, 2025 | globenewswire.comKronos Bio (KRON) to Release Quarterly Earnings on ThursdayKronos Bio (NASDAQ:KRON) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comKronos Bio (NASDAQ:KRON) Stock Price Down 1% - Should You Sell?Kronos Bio (NASDAQ:KRON) Stock Price Down 1% - What's Next?March 12, 2025 | marketbeat.comKronos Bio Insider Ups Holding By 36% During YearFebruary 23, 2025 | uk.finance.yahoo.comPartners Capital Investment Group LLP Sells 1,084,012 Shares of Kronos Bio, Inc. (NASDAQ:KRON)Partners Capital Investment Group LLP lessened its position in Kronos Bio, Inc. (NASDAQ:KRON - Free Report) by 67.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 527,500 shares of the company's stock afteFebruary 17, 2025 | marketbeat.comPeapod Lane Capital LLC Acquires Shares of 562,620 Kronos Bio, Inc. (NASDAQ:KRON)Peapod Lane Capital LLC bought a new stake in Kronos Bio, Inc. (NASDAQ:KRON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 562,620 shares of the company's stock, valued at approximately $534,00February 13, 2025 | marketbeat.comKronos Bio, Inc. (NASDAQ:KRON) Short Interest Up 16.5% in DecemberKronos Bio, Inc. (NASDAQ:KRON - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 577,700 shares, a growth of 16.5% from the December 15th total of 496,000 shares. Approximately 1.5% of the company's stock are sold short. Based on an average trading volume of 255,900 shares, the short-interest ratio is presently 2.3 days.January 19, 2025 | marketbeat.comWe Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth CarefullyJanuary 13, 2025 | uk.finance.yahoo.comKronos Bio (NASDAQ:KRON) Stock Price Down 1.8% - Here's What HappenedKronos Bio (NASDAQ:KRON) Trading Down 1.8% - What's Next?January 1, 2025 | marketbeat.comKronos Bio Ends Collaboration with Genentech and RocheDecember 27, 2024 | tipranks.comKronos Bio Inc Ordinary SharesDecember 13, 2024 | morningstar.comKronos Bio (NASDAQ:KRON) Shares Up 8.5% - Still a Buy?Kronos Bio (NASDAQ:KRON) Stock Price Up 8.5% - Still a Buy?December 6, 2024 | marketbeat.comStruggling Bay Area biotech firm Kronos, once worth $1B, lays off almost entire staffDecember 4, 2024 | msn.comKronos Bio announces workforce reduction of 83% by year-endNovember 28, 2024 | markets.businessinsider.comKronos Bio to lay off 83% of staff as CEO steps downNovember 28, 2024 | bizjournals.comBiotech with Cambridge lab slashes 83% of staff, CEO departsNovember 28, 2024 | bizjournals.comKronos Bio CEO Norbert Bischofberger steps down, Deborah Knobelman named interimNovember 28, 2024 | markets.businessinsider.comKronos Bio announces interim CEO; over 80% of staff reductionNovember 28, 2024 | msn.comKronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-UpNovember 28, 2024 | msn.comKronos Bio Announces CEO Transition and Reduction in ForceNovember 27, 2024 | globenewswire.comPetri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firmNovember 22, 2024 | bizjournals.comKronos Bio Third Quarter 2024 Earnings: Beats ExpectationsNovember 16, 2024 | finance.yahoo.comKronos Bio to present preclinical data from p300 KAT inhibitor programNovember 16, 2024 | markets.businessinsider.comKronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesNovember 15, 2024 | uk.finance.yahoo.comKronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024November 14, 2024 | globenewswire.comTD Cowen downgrades Kronos Bio (KRON) to a HoldNovember 14, 2024 | markets.businessinsider.comKronos Bio downgraded to Hold from Buy at TD CowenNovember 14, 2024 | markets.businessinsider.comKronos mulls ‘strategic alternatives’ after axing cancer drug developmentNovember 14, 2024 | yahoo.comKronos Bio (NASDAQ:KRON) Rating Lowered to "Neutral" at Piper SandlerPiper Sandler lowered shares of Kronos Bio from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $6.00 to $1.00 in a report on Thursday.November 14, 2024 | marketbeat.comKronos Bio (NASDAQ:KRON) Stock Rating Lowered by TD CowenTD Cowen downgraded Kronos Bio from a "buy" rating to a "hold" rating in a report on Thursday.November 14, 2024 | marketbeat.com Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address KRON Media Mentions By Week KRON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KRON News Sentiment▼0.910.88▲Average Medical News Sentiment KRON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KRON Articles This Week▼31▲KRON Articles Average Week Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CTMX News Today MNPR News Today ACIU News Today SOPH News Today AVTE News Today INBX News Today TVGN News Today DRUG News Today IPHA News Today CYBN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KRON) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KRON Stock Free KRON Stock Alerts